Cardiol Therapeutics Inc. (TSX:CRDL)
Canada · Delayed Price · Currency is CAD 1.390
+0.080 (6.11%)
Feb 3, 2026, 11:57 AM EST
Cardiol Therapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
145.33M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 78.76K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ascend Wellness Holdings | 718.79M |
| TerrAscend | 417.11M |
| Planet 13 Holdings | 151.05M |
| Auxly Cannabis Group | 146.00M |
| Medexus Pharmaceuticals | 145.00M |
| Cannara Biotech | 112.25M |
| HLS Therapeutics | 77.79M |
| Charlotte's Web Holdings | 68.58M |
Cardiol Therapeutics News
- 11 days ago - Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million - Newsfile Corp
- 18 days ago - Cardiol Therapeutics announces $13.5M bought-deal private placement - Seeking Alpha
- 18 days ago - Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Newsfile Corp
- 18 days ago - Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - Newsfile Corp
- 21 days ago - Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Newsfile Corp
- 6 weeks ago - Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research... • news - Onvista
- 2 months ago - Cardiol Therapeutics Inc To Present Phase II ARCHER Results Transcript - GuruFocus
- 2 months ago - Cardiol Therapeutics (CRDL): HC Wainwright & Co. Reiterates Buy Rating | CRDL Stock News - GuruFocus